1. Erythrocyte membrane coated with nitrogen-doped quantum dots and polydopamine composite nano-system combined with photothermal treatment of Alzheimer's disease.
- Author
-
Liu, Jichun, Chi, Mingyuan, Li, Lianxin, Zhang, Yuewen, and Xie, Meng
- Subjects
- *
ALZHEIMER'S disease , *QUANTUM dots , *ERYTHROCYTE membranes , *DOPING agents (Chemistry) , *NEAR infrared radiation , *CHELATING agents , *METAL ions , *ERYTHROCYTES , *BLOOD-brain barrier - Abstract
[Display omitted] • Erythrocyte membrane coated N -doped CQDs and polydopamine (PDA-CQD/RBC)were synthesized. • 808 nm NIR photo-thermolysis promotes the crossing of the blood–brain barrier by PDA-CQD/RBC. • PDA-CQD/RBC can regulate metal ion balance as well as clear abnormal ROS to reduce severe nerve. • The introduction of near infrared light and heat can depolymerize mature Aβ fibers. Mitochondrial dysfunction and metal ion imbalance are recognized as pathological hallmarks of Alzheimer's Disease (AD), leading to deposition of β-amyloid (Aβ) thereby and inducing neurotoxicity, activating apoptosis, eliciting oxidative stress, and ultimately leading to cognitive impairment. In this study, the red blood cell membrane (RBC) was used as a vehicle for encapsulating carbon quantum dots (CQD) and polydopamine (PDA), creating a nanocomposite (PDA-CQD/RBC). This nanocomposite was combined with near-infrared light (NIR) for AD treatment. The RBC offers anti-immunorecognition properties to evade immune clearance, PDA exhibits enzyme-mimicking activity to mitigate oxidative stress damage, and CQD acts as a chelating agent for metal ions (Cu2+), effectively preventing Cu2+-mediated aggregation of Aβ. Furthermore, the local heating induced by near-infrared laser irradiation can dismantle the formed Aβ fibers and enhance the blood–brain barrier's permeability. Both in vitro and animal experiments have shown that PDA-CQD/RBC, in combination with NIR, mitigates neuroinflammation, and ameliorates behavioral deficits in mice. This approach targets multiple pathological pathways, surpassing the limitations of single-target treatments and enhancing therapeutic efficacy while decelerating disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF